You are here
Eflornithine Does Not Improve Outcome in Superficial Bladder Cancer
January 16, 2004
SAN ANTONIO--(BUSINESS WIRE)--Jan. 15, 2004--ILEX(tm) Oncology Inc. (Nasdaq:ILXO - News) announced today that the investigational agent eflornithine (DFMO), which was being studied by ILEX in collaboration with the National Cancer Institute (NCI) in a Phase III placebo-controlled trial of patients with superficial bladder cancer, did not prevent the recurrence of cancer more so than placebo and that the trial has been discontinued. The findings of an independent data monitoring board determined that no statistical significance among the treatment arms was observed.
The NCI is continuing to study the agent in a number of clinical settings.
Source: ILEX Oncology Inc.
May Solve Two Problems at Once
Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen
Zip Device Faster to Apply, Minimizes Scarring
Finding Could Spur New Targeted Treatments
But a ‘Serendipitous’ Finding Could Provide a Solution
New Drug Could Make Ears “Young” Again
DNA Changes May Help Predict Women at Risk